Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab in Mild and Moderate COVID-19
NCT05679492Phase 3Withdrawn
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of meplazumab in coronavirus disease 2019 (COVID-19), sponsored by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.. Planned start May 2023; status: withdrawn.
02
Drugs
meplazumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05679492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679492.